Saman­tha Truex's Quench Bio calls it quits af­ter fail­ing to solve the Gas­der­min D in­flam­ma­tion puz­zle

At the core of the bio­phar­ma in­dus­try is an ex­per­i­men­tal sci­ence. Every com­pa­ny and biotech out there hopes to one day prove their hy­pothe­ses and cre­ate im­pact­ful med­i­cines that can help pa­tients.

But sci­ence is messy, and some­times those ex­per­i­ments don’t end up work­ing as planned.

Quench Bio, the Cam­bridge, MA-based biotech look­ing for new ways to tar­get the gene Gas­der­min D in treat­ing in­flam­ma­to­ry dis­eases, has de­cid­ed to wind down op­er­a­tions af­ter the gene proved “un­drug­gable” with their tech­nol­o­gy. The com­pa­ny an­nounced the news in a Twit­ter thread Tues­day morn­ing, and in an ef­fort to keep Gas­der­min pro­grams mov­ing for­ward, auc­tioned off its re­search.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER